Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Fabienne Guillaumond

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7456-7315; OpenAlex author ID A5047258963. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
58
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 3 papers · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 16

  1. Co-translational O-glycosylation driven by GALNTs spatial reprogramming fosters pancreatic cancer growth Co-author DOI 10.64898/2026.09.04.749345↗
  2. The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. Co-author DOI 10.1126/sciadv.adu2276↗
  3. Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. Co-author DOI 10.1016/j.isci.2023.106899↗
  4. Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer. Co-author DOI 10.1038/s41467-022-29659-w↗
  5. CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. Co-author DOI 10.1126/scisignal.abg8191↗
  6. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. Co-author DOI 10.15252/embj.2021110466↗
  7. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s42003-021-02508-0↗
  8. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. Co-author DOI 10.1158/0008-5472.can-15-2790↗
  9. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  10. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Co-author DOI 10.1038/ncomms16031↗
  11. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/cdd.2016.18↗
  12. Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling. Co-author DOI 10.1038/cddis.2014.557↗
  13. [Pancreatic adenocarcinoma: a tumor highly dependent on lipoproteins]. First author DOI 10.1051/medsci/20153108009↗
  14. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1421601112↗
  15. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1219555110↗
  16. The metabolic facet of pancreatic cancer: how hypoxia shapes fatal cancer cells. Co-author DOI 10.4161/cc.24489↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sophie Vasseur · 14 shared papers, 2013–2026 · strength 1.30
  2. Richard Tomasini · 12 shared papers, 2013–2026 · strength 1.19
  3. Juan Iovanna · 11 shared papers, 2013–2023 · strength 0.83
  4. Nelson Dusetti · 7 shared papers, 2013–2026 · strength 0.73
  5. François Bertucci · 4 shared papers, 2021–2025 · strength 0.56
  6. Jérémy Nigri · 7 shared papers, 2015–2022 · strength 0.56
  7. Julie Leca · 6 shared papers, 2013–2022 · strength 0.44
  8. Tristan Gicquel · 3 shared papers, 2017–2023 · strength 0.32
  9. Rebecca Bennion · 1 shared paper, 2026 · strength 0.24
  10. Frédéric Bard · 1 shared paper, 2026 · strength 0.24
  11. Eric Mas · 1 shared paper, 2026 · strength 0.24
  12. Brice Chanez · 1 shared paper, 2026 · strength 0.24
  13. Martin James Humphries · 1 shared paper, 2026 · strength 0.24
  14. Odile Gayet · 3 shared papers, 2015–2023 · strength 0.23
  15. Victoire Gouirand · 3 shared papers, 2015–2022 · strength 0.20
  16. Zainab Hussain · 1 shared paper, 2025 · strength 0.20
  17. Georgios Efthymiou · 1 shared paper, 2025 · strength 0.20
  18. Julie Roques · 4 shared papers, 2015–2018 · strength 0.20
  19. Véronique Secq · 4 shared papers, 2015–2018 · strength 0.20
  20. Mehdi Ouaïssi · 4 shared papers, 2015–2018 · strength 0.18
  21. Jared R. Mayers · 2 shared papers, 2017–2022 · strength 0.17
  22. Matthew G. Vander Heiden · 2 shared papers, 2017–2022 · strength 0.17
  23. Christian Bressy · 3 shared papers, 2015–2018 · strength 0.15
  24. Nadine Abdel Hadi · 1 shared paper, 2023 · strength 0.15
  25. Rawand Masoud · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.